Published • loading... • Updated
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Argus
Summary by thecerbatgem.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Argus
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) was upgraded by stock analysts at Argus from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a $850.00 price objective on the biopharmaceutical company’s stock. Argus’ target price suggests a potential upside of 12.10% […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
